Along with trastuzumab, various anti-HER2 monoclonal antibodies, including afatinib, gefitinib, neratinib, or lapatinib, individually or in conjunction with standard therapies, have helped to expand the range of therapeutic choices available to breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.